ArQule Message Board - Msg: 5212661

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ArQule

ARQL 20.00

0.0%

Jan 16 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Mike McFarland who wrote (256)	7/16/1998 8:13:00 AM
From: Dr. John M. de Castro	Read Replies (1) of 399

This is what I find interesting in the quarterly report: "Principal areas of investment have been in the areas of proprietary chemistries, cheminformatics and continuing development of its world-class screening capability at ArQule's new Waltham, Massachusetts facility........." "In addition, we began applying our in-house high throughput screening capabilities to our recent collaborations with Immunex and Genome therapeutics, enabling us to further accelerate the drug discovery process for each of these collaborators.'' " ARQL appears to be transiting from a supplier of molecules for drug discovery into a drug discovery company. There was little or no fanfare about this development. But, this could be very significant. John de C

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next